DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer

  • Recurrent or persistent disease

• Meets 1 of the following criteria:

  • Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest dimension to be recorded) as ≥ 20 mm by chest x-ray OR as ≥ 10 mm by spiral CT scan, MRI, or caliper measurement by clinical exam

    • Must have ≥ 1 "target lesion" that can be used to assess response to study treatment as defined by RECIST criteria

      • Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days following completion of radiotherapy
    • Lymph nodes must be ≥ 15 mm in short axis by CT scan or MRI

  • Detectable disease, defined as non-measurable disease meeting ≥ 1 of the following criteria:

    • CA-125 ≥ 2 times upper limit of normal (ULN) at baseline
    • Ascites and/or pleural effusion attributed to tumor
    • Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST criteria definitions for target lesions

• Must have received 1 prior platinum-based chemotherapeutic regimen that contained carboplatin, cisplatin, or another organoplatinum compound for management of the primary disease

  • Initial treatment may have included intraperitoneal therapy, consolidation therapy, non-cytotoxic therapy, or extended therapy administered after surgical or non-surgical assessment

  • Prior biologic (non-cytotoxic) therapy as part of the primary treatment regimen allowed

    • No prior non-cytotoxic therapy for management of recurrent or persistent disease
  • Two additional prior cytotoxic regimens for management of recurrent or persistent disease allowed (≤ 1 non-platinum, non-taxane regimen allowed)
  • Patients who have received only one prior cytotoxic regimen (i.e., platinum-based regimen for management of primary disease) must have a platinum-free interval of < 12 months OR have progressed during platinum-based therapy OR have persistent disease after platinum-based therapy
• Not eligible for a higher priority GOG clinical trial (i.e., any active phase III GOG protocol or Rare Tumor protocol for the same patient population)
• No history or evidence of CNS disease by physical exam, including primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

• GOG performance status (PS) 0-2 (for patients who have had 1 prior treatment)
• GOG PS 0-1 (for patients who have had 2 or 3 prior treatments)
• ANC ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.5 times ULN
• Bilirubin ≤ 1.5 times ULN
• SGOT ≤ 3.0 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• PT/INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if the patient is on a stable dose of therapeutic warfarin for management of deep vein thrombosis, including pulmonary embolism)
• PTT ≤ 1.5 times ULN
• Fasting serum cholesterol ≤ 300 mg/dL (or ≤ 7.75 mmol/L) AND fasting triglycerides ≤ 300 mg/dL (or ≤ 3.42 mmol/L)
• Urine protein:creatinine ratio < 1.0
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other invasive malignancies within the past 3 years except nonmelanoma skin cancer

• No clinically significant cardiovascular disease, including any of the following:

  • Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction or unstable angina within the past 6 months
  • NYHA class II-IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication (asymptomatic, atrial fibrillation with controlled ventricular rate allowed)
  • Ejection fraction < 50% in patients who received prior treatment with an anthracycline (including doxorubicin hydrochloride and/or liposomal doxorubicin hydrochloride)
  • Peripheral vascular disease ≥ CTCAE grade 2 (i.e., at least brief [< 24 hours] episodes of ischemia managed non-surgically and without permanent deficit)
  • Cerebrovascular accident or transient ischemic attack within the past 6 months
• No acute hepatitis or active infection requiring parenteral antibiotics (except for uncomplicated urinary tract infection)
• No history or evidence of seizures not controlled with standard medical therapy
• No subarachnoid hemorrhage within the past 6 months
• No active bleeding or pathologic condition that carries a high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)
• No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days
• No clinical symptoms or signs of GI obstruction or requirement for parenteral hydration and/or nutrition
• No serious non-healing wound, ulcer, or bone fracture
• No known hypersensitivity to murine or chimeric antibodies
• No other medical history or condition that, in the opinion of the investigator, would preclude study participation

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior surgery, radiotherapy, or chemotherapy
• No prior everolimus or any other mTOR inhibitor
• No prior cancer treatment that would contraindicate study therapy

• No prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the past 5 years

  • Prior radiotherapy for localized cancer of the breast, head and neck, or skin allowed provided it was completed > 3 years ago and the patient remains free of recurrent or metastatic disease

• No prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the past 5 years

  • Prior adjuvant chemotherapy for localized breast cancer allowed provided it was completed > 3 years ago and the patient remains free of recurrent or metastatic disease
• At least 12 weeks since prior chimeric, human, or humanized monoclonal antibodies (including bevacizumab) or VEGF receptor fusion protein (including aflibercept)
• More than 30 days since prior and no other concurrent investigational therapy
• More than 28 days since prior major surgery
• At least 3 weeks since any other prior therapy directed at the malignant tumor, including biological or immunologic agents (small molecules or murine monoclonal antibodies)
• At least 1 week since prior hormonal therapy directed at the malignant tumor
• No other concurrent anticancer agents
• No concurrent chronic treatment with systemic steroids or other immunosuppressive agents
• Concurrent warfarin allowed for prophylaxis or treatment of thrombosis
• Concurrent low molecular weight heparin allowed provided PT/INR is ≤ 1.5
• Concurrent low-dose aspirin (≤ 325 mg/day) allowed for patients at a higher risk for arterial thromboembolic disease